Elysium Health is a health startup that is translating advances in science and technology into clinically-validated health products that work.
Elysium’s mission is to help people live healthier, longer.
Elysium Health was co-founded by the scientist Dr. Leonard Guarente. Dr. Guarente has conducted significant research on the molecular and genetic causes of aging during his long career as the director of the Paul F. Glenn Center for Biology of Aging Research at MIT.
Elysium Health sells a supplement called Basis. Basis is clinically proven to increase levels of NAD+ in our bodies. NAD+ is a coenzyme that is essential to many of our cellular functions, like energy creation, DNA protection, and circadian rhythms. As we age, the levels of NAD+ naturally decline and those functions break down. (More How To Be Preventative About Your Health)
Basis is a vegetarian, vegan, gluten- and nut-free supplement. This allows you to take the supplement, even if you are on a strict diet or have allergies to consider.
Basis underwent a clinical trial in 2016. The results of the trial demonstrated d that Basis increases levels of NAD+ in humans by an average of 40 percent when taken daily at the recommended dose (two capsules) over the course of several weeks. The results were published in the peer-reviewed science journal npj: Aging and Mechanisms of Disease.
To purchase Basis, visit Elysium Health’s website. The company sells Basis as monthly subscriptions. A standard monthly subscription to Basis costs $50 per month. Prepaying for a longer subscription decreases the monthly cost to between $40 and $45. You can also buy a single jar of Basis for $60.
Elysium Health is also in the process of developing new products that focus on the microbiome, cognitive health, skin health, muscle function, and circadian rhythms. These products are in various stages of pre-clinical and clinical trials.
More information on Elysium Health, the company’s team, and the science behind Basis can be found on Elysium’s website by Clicking This Link.
Follow them on Twitter.